Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems • Medical Devices & Mechanical Engineering
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ is managing 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 4 distinct examiners and 4 distinct art units, indicating that each pending matter is being reviewed independently by a different examiner in a different art unit. This matching count between actions, examiners, and art units suggests a prosecution landscape where each case follows its own administrative path.
The busiest examiner, BAEK, BONG-SOOK, is currently handling 1 pending office action. Given that there are 4 pending actions and 4 distinct examiners, the workload is distributed so that each examiner, including BAEK, BONG-SOOK, manages 1 pending action for the university. For the practitioner, this means that there is no central examiner or art unit to focus on, requiring a unique strategy for each of the 4 actions to address the specific requirements of 4 different reviewers across 4 separate technical groups.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (20%) |
| Multi-statute (no §101) | 4 (80%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAEK, BONG-SOOK | 1 | 41.7% | +69.9% |
| RAMSEY, JEREMY C | 1 | 52.5% | +46.9% |
| BANERJEE, KOYELI | 1 | 50.0% | +0.0% |
| BERHANU, ETSUB D | 1 | 65.3% | +24.8% |
| MCCOLLUM, ANDREA K | 1 | 60.7% | +32.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18029149 | Method for classifying a polysomnography recording into defined sleep stages | BERHANU, ETSUB D | 16d |
| 18730744 | ROLLER SHUTTER ROD AND ROLLER SHUTTER | RAMSEY, JEREMY C | 22d |
| 18836398 | Compositions and kits for use in wound healing, tissue regeneration and/or bone regeneration | BAEK, BONG-SOOK | — |
| 18567625 | METHODS AND COMPOSITIONS FOR TREATMENT OF AUTOIMMUNE CONDITIONS | BANERJEE, KOYELI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16970688 | Novel IL-4-/IL-13-derived peptide compounds for the treatment or prevention of neurodegenerative or neuroinflammatory diseases | MCCOLLUM, ANDREA K | 99d overdue |
| 18029149 | Method for classifying a polysomnography recording into defined sleep stages | BERHANU, ETSUB D | 16d |
| 18730744 | ROLLER SHUTTER ROD AND ROLLER SHUTTER | RAMSEY, JEREMY C | 22d |
| 18836398 | Compositions and kits for use in wound healing, tissue regeneration and/or bone regeneration | BAEK, BONG-SOOK | — |
| Art Unit | Apps |
|---|---|
| 1611 | 1 |
| 3634 | 1 |
| 1658 | 1 |
| 3791 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18836398 | Compositions and kits for use in wound healing, tissue regeneration and/or bone regeneration | BAEK, BONG-SOOK | 1611 | §102§103§112 | Non-Final OA | — | Pending | Aug 07, 2024 |
| 18730744 | ROLLER SHUTTER ROD AND ROLLER SHUTTER | RAMSEY, JEREMY C | 3634 | §102§103§112 | Final Rejection | 22d | Pending | Jul 19, 2024 |
| 18567625 | METHODS AND COMPOSITIONS FOR TREATMENT OF AUTOIMMUNE CONDITIONS | BANERJEE, KOYELI | 1658 | §102§103 | Non-Final OA | — | Pending | Dec 06, 2023 |
| 18029149 | Method for classifying a polysomnography recording into defined sleep stages | BERHANU, ETSUB D | 3791 | §103§112Other | Non-Final OA | 16d | Pending | Mar 29, 2023 |
| 16970688 | Novel IL-4-/IL-13-derived peptide compounds for the treatment or prevention of neurodegenerative or neuroinflammatory diseases | MCCOLLUM, ANDREA K | 1674 | §112 | Non-Final OA | 99d overdue | Pending | Aug 18, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial